Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
3 September 2019

ORYZON to present at upcoming international conferences

9 August 2019

Oryzon to present at upcoming international conferences

30 July 2019

ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019

29 July 2019

ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD

25 July 2019

ORYZON raises its share capital by EUR 20 Million through a private placement

16 July 2019

ORYZON presents data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

14-18 July 2019

2019 Alzheimer's Association International Conference (AAIC-2019)

Los Angeles Convention Center

CA

United States

10 July 2019

ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

14 June 2019

ORYZON presents preliminary dose finding results of Phase II trial with iadademstat in AML

3 June 2019

ORYZON to present first clinical data from ALICE Phase IIa trial with iadademstat at the 24th Congress of the European Hematology Association

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Current page 39
  • Page 40
  • Page 41
  • Page 42
  • Page 43
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel